A new analysis published in Nature Medicine reports on Mar. 22 that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of major cardiovascular events and end-stage kidney disease in people with type 1 diabetes, without increasing hospitalizations for diabetic ketoacidosis or severe hypoglycemia.
The findings are significant because they suggest GLP-1RAs, already used for type 2 diabetes and obesity, could also benefit those with type 1 diabetes—a group historically excluded from large clinical trials of these drugs. The study highlights a potential new approach to managing long-term complications associated with type 1 diabetes.
Researchers analyzed data from more than 174,000 patients over a decade using "target trial emulation," a method designed to mimic randomized clinical trials by applying statistical techniques to observational data. Patients who started GLP-1RA therapy had a 15% lower risk of major cardiovascular events and a 19% reduced risk of end-stage kidney disease compared to those who did not use these medications. The analysis also found no increased risk of hospitalization for diabetic ketoacidosis or severe hypoglycemia among users.
The study drew on the Optum Labs Data Warehouse, which contains de-identified health records for over 300 million patients. Researchers compared outcomes between those who initiated GLP-1RA treatment and those who did not, using propensity score weighting to balance differences between groups such as age and existing health conditions. Over five years, GLP-1RA users saw reductions not only in heart and kidney risks but also in heart failure (18% lower risk) and major adverse liver events (28% lower risk). Users were also more likely to achieve meaningful weight loss.
Despite these promising results, the authors caution that their findings are based on observational data rather than randomized controlled trials. They note limitations such as an inability to track exact insulin dose adjustments or compare specific GLP-1RA agents or dosages. The researchers call for large-scale randomized studies to confirm these results and determine optimal treatments for people with type 1 diabetes.
If confirmed by future research, these findings could expand treatment options for individuals living with type 1 diabetes, potentially improving long-term health outcomes beyond current standards focused mainly on blood sugar control.
